Treatment
Monoclonal antibody clinical trials
We’re tracking 156 recruiting studies that include Monoclonal antibody, each written for real people, not researchers, below.
Recruiting studies
- NCT07355699RecruitingPhase 4
Orelabrutinib for untreated marginal zone lymphoma
This trial tests a new targeted drug (orelabrutinib) with or without another drug that targets CD20 (a protein on some immune cells) for people with untreated marginal zone lymphoma. It aims to see if this combination works better than other treatments and may be an option for those who cannot have radiation.
BeijingAges 18 years+ - NCT02395497RecruitingPhase 2/Phase 3
Penile transplant trial using immune-suppressing medicines
This study tests whether a donated penis can be successfully transplanted using medicines that calm the immune system to prevent rejection. It also looks at safety and recovery of function in men with severe penile loss from injury, cancer surgery, or birth conditions.
Baltimore, MarylandAges 18–69 - NCT07400354Recruiting
PD-1 drug plus chemo for advanced stomach cancer based on gut bacteria
This trial tests if adding a PD-1 immunotherapy drug to standard chemotherapy works better for advanced stomach cancer, and looks at how your gut bacteria may affect treatment. It is for people who have not had chemotherapy before and are starting their first treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07444437RecruitingPhase 2
LM103 after surgery for lung cancer
This trial tests if LM103, given after surgery and standard chemotherapy, helps prevent non-small cell lung cancer from coming back. It is for people who have already had chemotherapy or immunotherapy before surgery and whose cancer did not return after surgery.
Guangzhou, GuangdongAges 18–75 - NCT07512362RecruitingPhase 2
Stem cells and antibodies for early Alzheimer's disease
This study tests whether human stem cells, combined with your existing Alzheimer's medication (Leqembi or Kisunla), can help slow memory loss and improve daily functioning in people with mild cognitive impairment or early Alzheimer's. You would receive a stem cell infusion as an add-on to your current treatment.
Miami, FloridaAges 55–90 - NCT07586891Recruiting
Low-Branched-Chain Amino Acid Diet With Immunotherapy for Stage III Melanoma
This trial tests whether a special diet low in certain amino acids (building blocks of protein), combined with an immune-boosting antibody drug, can safely shrink stage III melanoma that has spread to lymph nodes. The goal is to see if this combination works better than standard treatment.
Xi'anAges 18–75 - NCT06726096Enrolling by invitationPhase 3
Trial of VDJ001 for moderate to severe rheumatoid arthritis
This trial tests a new medicine called VDJ001 for people with moderate to severe rheumatoid arthritis who are already taking methotrexate. The goal is to see if VDJ001 helps reduce joint pain and swelling better than a placebo.
Beijing, Beijing MunicipalityAges 18–75 - NCT07713485RecruitingPhase 1
XmAb412 study in healthy adults
This is a first-in-human study testing a new drug called XmAb412 in healthy volunteers. It helps researchers understand how the drug works in the body and if it's safe.
Joondalup, Western AustraliaAges 18–55 - NCT06885957Recruiting
Monoclonal antibodies for AQP4-positive NMOSD
This trial is testing monoclonal antibody treatments for people with a specific type of neuromyelitis optica spectrum disorder (NMOSD) caused by AQP4 antibodies. It aims to see if these targeted therapies can help control the disease and prevent relapses.
Wuhan, HubeiAges 18–65 - NCT06668727RecruitingPhase 1
Testing a new antibody for hepatitis B safety
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
Aarhus NAges 18–70 - NCT07610772RecruitingPhase 1
Safety study of a new hepatitis B antibody for hepatitis D
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
AarhusAges 18–70 - NCT04335383Recruiting
Study blood antibodies for a Pseudomonas-targeting treatment
This study looks at people’s blood to see if they already have antibodies that recognize Pseudomonas aeruginosa, a type of bacteria. If you qualify for the prospective part, they may collect blood samples at Grenoble University Hospital and use your results to support future treatment testing.
GrenobleAges 18 years+
Common questions
- Are there clinical trials studying Monoclonal antibody?
- Yes. Clin2 currently lists 156 recruiting studies that include Monoclonal antibody, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Monoclonal antibody trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Monoclonal antibody an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Monoclonal antibody or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.